Development and validation of a multivariate model for predicting heart failure hospitalization and mortality in patients receiving maintenance hemodialysis

被引:1
作者
Tang, Wenwu [1 ]
Zhang, Ying [1 ]
Wang, Zhixin [1 ]
Yuan, Xinzhu [1 ]
Chen, Xiaoxia [2 ]
Yang, Xiaohua [3 ]
Qi, Zhirui [4 ]
Zhang, Ju [3 ]
Li, Jie [5 ]
Xie, Xisheng [1 ]
机构
[1] Nanchong Cent Hosp, Clin Coll 2, Nanchong North Sichuan Med Coll, Dept Nephrol, Nanchong, Peoples R China
[2] Suining Cent Hosp, Dept Nephrol, Suining, Peoples R China
[3] Guangyuan Cent Hosp, Dept Nephrol, Guangyuan, Peoples R China
[4] North Sichuan Med Coll, Nanchong, Peoples R China
[5] Sichuan Med Coll, Gen Practice Dept Nanchong North, Nanchong, Peoples R China
关键词
Patients on MHD; heart failure; mortality; predictive model; retrospective study; KIDNEY-DISEASE; CARDIOVASCULAR-DISEASE; ASSOCIATION; OUTCOMES; ADULTS;
D O I
10.1080/0886022X.2023.2255686
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background Heart failure (HF) in patients undergoing maintenance hemodialysis (MHD) increases their hospitalization rates, mortality, and economic burden significantly. We aimed to develop and validate a predictive model utilizing contemporary deep phenotyping for individual risk assessment of all-cause mortality or HF hospitalization in patients on MHD.Materials and Methods A retrospective review was conducted from January 2017 to October 2022, including 348 patients receiving MHD from four centers. The variables were adjusted by Cox regression analysis, and the clinical prediction model was constructed and verified.Results The median follow-up durations were 14 months (interquartile range [IQR] 9-21) for the modeling set and 14 months (9-20) for the validation set. The composite outcome occurred in 72 (29.63%) of 243 patients in the modeling set and 39 (37.14%) of 105 patients in the validation set. The model predictors included age, albumin, history of cerebral hemorrhage, use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers/"sacubitril/valsartan", left ventricular ejection fraction, urea reduction ratio, N-terminal prohormone of brain natriuretic peptide, and right atrial size. The C-index was 0.834 (95% CI 0.784-0.883) for the modeling set and 0.853 (0.798, 0.908) for the validation set. The model exhibited excellent calibration across the complete risk profile, and the decision curve analysis (DCA) suggested its ability to maximize patient benefits.Conclusion The developed prediction model offered an accurate and personalized assessment of HF hospitalization risk and all-cause mortality in patients with MHD. It can be employed to identify high-risk patients and guide treatment and follow-up.
引用
收藏
页数:13
相关论文
共 46 条
  • [1] Heidenreich Paul A, 2022, Circulation, V145, pe895, DOI [10.1161/CIR.0000000000001073, 10.1161/CIR.0000000000001063]
  • [2] [Anonymous], 2018, Am J Kidney Dis, V71, pS417, DOI [10.1053/j.ajkd.2018.01.021, DOI 10.1053/J.AJKD.2018.01.021]
  • [3] Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome
    Bart, Bradley A.
    Goldsmith, Steven R.
    Lee, Kerry L.
    Givertz, Michael M.
    O'Connor, Christopher M.
    Bull, David A.
    Redfield, Margaret M.
    Deswal, Anita
    Rouleau, Jean L.
    LeWinter, Martin M.
    Ofili, Elizabeth O.
    Stevenson, Lynne W.
    Semigran, Marc J.
    Felker, G. Michael
    Chen, Horng H.
    Hernandez, Adrian F.
    Anstrom, Kevin J.
    McNulty, Steven E.
    Velazquez, Eric J.
    Ibarra, Jenny C.
    Mascette, Alice M.
    Braunwald, Eugene
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (24) : 2296 - 2304
  • [4] Right ventricle in heart failure with preserved ejection fraction
    Berglund, Felix
    Pina, Pamela
    Herrera, Cesar J.
    [J]. HEART, 2020, 106 (23) : 1798 - +
  • [5] Predicting hospitalisation for heart failure and death in patients with, or at risk of, heart failure before first hospitalisation: a retrospective model development and external validation study
    Bradley, Joshua
    Schelbert, Erik B.
    Bonnett, Laura J.
    Lewis, Gavin A.
    Lagan, Jakub
    Orsborne, Christopher
    Brown, Pamela F.
    Naish, Josephine H.
    Williams, Simon G.
    McDonagh, Theresa
    Schmitt, Matthias
    Miller, Christopher A.
    [J]. LANCET DIGITAL HEALTH, 2022, 4 (06): : E445 - E454
  • [6] Bustamante Alejandro, 2016, J Circ Biomark, V5, p1849454416668791, DOI 10.1177/1849454416668791
  • [7] The prognostic value of URR equals that of Kt/V for all-cause mortality in Taiwan after 10-year follow-up
    Chen, Yi-Kong
    Chu, Chih-Sheng
    Niu, Sheng-Wen
    Lin, Hugo You-Hsien
    Yu, Pei-Hua
    Shen, Feng-Ching
    Chao, Yu-Lin
    Kuo, I-Ching
    Hung, Chi-Chih
    Chang, Jer-Ming
    [J]. SCIENTIFIC REPORTS, 2023, 13 (01)
  • [8] Cardiovascular disease in dialysis patients
    Cozzolino, Mario
    Mangano, Michela
    Stucchi, Andrea
    Ciceri, Paola
    Conte, Ferruccio
    Galassi, Andrea
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 : 28 - 34
  • [9] Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care
    Desai, Rishi J.
    Patorno, Elisabetta
    Vaduganathan, Muthiah
    Mahesri, Mufaddal
    Chin, Kristyn
    Levin, Raisa
    Solomon, Scott D.
    Schneeweiss, Sebastian
    [J]. HEART, 2021, 107 (17) : 1407 - 1416
  • [10] Clinical risk prediction model for 30-day all-cause re-hospitalisation or mortality in patients hospitalised with heart failure
    Driscoll, A.
    Romaniuk, H.
    Dinh, D.
    Amerena, J.
    Brennan, A.
    Hare, D. L.
    Kaye, D.
    Lefkovits, J.
    Lockwood, S.
    Neil, C.
    Prior, D.
    Reid, C. M.
    Orellana, L.
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 350 : 69 - 76